Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants [0.03%]
一项在健康受试者中评估伊曲康唑或利福平对口服齐鲁替尼药代动力学影响的临床试验
Yan-Ou Yang,Xiaohua Gong,Phillip Wang et al.
Yan-Ou Yang et al.
Zilurgisertib is an oral, activin receptor-like kinase 2 (ALK2) inhibitor being developed for the treatment of patients with fibrodysplasia ossificans progressiva. In vitro metabolism studies suggest zilurgisertib is primarily eliminated vi...
Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed-Dose Combination Versus Single-Component Tablets in Healthy Korean Males [0.03%]
一项针对健康韩国男性的临床试验：评估多奈哌齐和美金刚复方固定剂量组合片(10/20毫克)与单组分片剂的生物等效性研究
Minkyu Choi,Byung Hak Jin,Do Hoon Keum et al.
Minkyu Choi et al.
A fixed-dose combination (FDC) tablet formulation of donepezil/memantine (10/20 mg) was developed to improve medication compliance in patients with Alzheimer's disease (AD). This study compared the pharmacokinetic (PK) characteristics and s...
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study [0.03%]
微孔径示踪剂介导的伯佐塞替布（[14C]BZH，ATR抑制剂）在晚期实体瘤患者群体中质量平衡、药代动力学及排泄研究：一项一期临床试验
Jayaprakasam Bolleddula,Holger Scheible,Florian Huber et al.
Jayaprakasam Bolleddula et al.
Berzosertib is a small-molecule ataxia telangiectasia and Rad3-related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2-period, open-label study was conducted in adults with advanced solid tumors who were...
Combined Immediate-Release and Extended-Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation [0.03%]
立稳血液中药钠 Valproate结合速效及缓释成分可稳定抑制组蛋白去乙酰基化作用
Nikhil Ahuja,Susanna Kääriäinen,Zsófia Lovró et al.
Nikhil Ahuja et al.
A modified controlled-release sodium valproate formulation (VAL001, test) was compared with an approved enteric-coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to b...
A Randomized Thorough QT Trial Using Concentration-QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization [0.03%]
浓度-QT分析评价顺坦法丁心脏复极化影响的随机 thorough qt 试验
Osman S Turkoglu,Xiaofeng Wang,Jennifer Repella-Gordon et al.
Osman S Turkoglu et al.
Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder. This double-blind, placebo- and moxifloxacin-controlled, 3-period crossover trial evaluated th...
Pharmacokinetics and Safety Study of HN0141, a Novel Anti-Human Cytomegalovirus Inhibitor, in Healthy Volunteers [0.03%]
HN0141在健康受试者中的药代动力学及安全性研究是一项针对新型抗人巨细胞病毒抑制剂的研究
George Hill,Hong Gao,Yingzhe Fan et al.
George Hill et al.
HN0141 is a human cytomegalovirus (HCMV) DNA terminase complex inhibitor being developed for prophylaxis and/or preemptive treatment of HCMV infection and diseases. This study evaluated the safety, tolerability, and pharmacokinetics (PK) of...
Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study [0.03%]
针对中国受试者给予多纳单抗的安全性、耐受性和药代动力学：一项随机、双盲、安慰剂对照I期临床试验
Junyu Xu,Nan Zhao,Yihui Wang et al.
Junyu Xu et al.
Alzheimer's disease (AD), characterized by β-amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. Thi...
Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open-Label, Phase I Study [0.03%]
中度至重度肝功能不全对valemetostat药代动力学影响的开放性I期研究
Masaya Tachibana,Thuy Vu Craveiro,Thomas C Marbury et al.
Masaya Tachibana et al.
Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma. This Phase I, ...
Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects [0.03%]
评估健康受试者CYP3A抑制和诱导对呋喹替尼药代动力学潜在影响的评价
Martha Gonzalez,Zhao Yang,William R Schelman et al.
Martha Gonzalez et al.
Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2-part, 2-period fixed-sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinet...
Pharmacokinetics and Safety Evaluation of a New Generic Sitafloxacin: A Phase I Bioequivalence Study in Healthy Chinese Participants [0.03%]
盐酸西他沙星药代动力学及安全性评价——健康受试者中的I期生物等效性研究
Yongfang Lei,Pan Luo,Yuzhu Chen et al.
Yongfang Lei et al.
Sitafloxacin is a new antibiotic drug belonging to the fourth generation quinolone antibiotics. The aim of this study was to evaluate the pharmacokinetics (PK), safety profiles, and bioequivalence of test and reference 50-mg sitafloxacin ta...